Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SGR-2921 |
Synonyms | |
Therapy Description |
SGR-2921 is a CDC7 inhibitor, which potentially decreases proliferation and inhibits tumor growth (Blood (2022) 140 (Supplement 1): 5961–5962). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGR-2921 | SGR 2921|SGR2921 | CDC7 Inhibitor 4 | SGR-2921 is a CDC7 inhibitor, which potentially decreases proliferation and inhibits tumor growth (Blood (2022) 140 (Supplement 1): 5961–5962). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05961839 | Phase I | SGR-2921 | Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |